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Backgroud: Polycystic Ovary Syndrome (PCOS) is a multifactorial pathology that affects 10% of the women in
reproductive age being the main cause of infertility due to menstrual dysfunction. Since 1980, it is known that
PCOS is associated with insulin resistance (IR). The recognition of this association has prompted extensive
investigation on the relationship between insulin and gonadal function, and has turned insulin sensitizer agent as
the main therapeutic choice. In particular two different polyalcohol myo-inositol and D-chiro-inositol have been
shown to improve insulin resistance, hyperandrogenism and to induce ovulation in PCOS women. In particular,
while data on myo-inositol and restored ovulation were consistent, data on D-chiro-inositol were not . Recently, a
comparative study, proposed a D-chiro-inositol paradox in the ovary of PCOS patients hypothesizing that only myo-
inositol has a specific ovarian action. In the present study we aim to further study the role played by D-chiro-
inositol at ovarian level.
Methods: A total of 54 women, aged <40 years and diagnosed with PCOS were enrolled in this study. Patients
with insulin resistance and/or hyperglycaemia were excluded from the study. Patients were randomly divided into 5
groups (n=10-12): a placebo group, and 4 groups (A-D) that received 300-600-1200-2400 mg of DCI daily
respectively. All treatments were carried out for 8 weeks before follicle stimulating hormone (rFSH) administration.
Results: Total r-FSH units increased significantly in the two groups that received the higher doses of DCI. The
number of immature oocytes was significantly increased in the three groups that received the higher doses of DCI.
Concurrently, the number of MII oocytes was significantly lower in the D group compared to placebo group.
Noteworthy, the number of grade I embryos was significantly reduced by DCI supplementation.
Conclusions: Indeed, increasing DCI dosage progressively worsens oocyte quality and ovarian response.Introduction
Polycystic Ovary Syndrome (PCOS) is a multifactorial
pathology that affects 10% of the women in reproductive
age being the main cause of infertility due to menstrual
dysfunction[1-3]. Diagnosis is based on three different
factors, identified during a consensus meeting sponsored
by the European Society for Human Reproduction and
Embryology (ESHRE) and the American Society for Re-
productive Medicine (ASRM) held in Rotterdam in
2003: (1) oligo-anovulation, (2) hyperandrogenism (clin-
ical or biochemical) and (3) the presence of 12 or more
follicles in each ovary measuring 2–9 mm in diameter,
and/or an increased ovarian volume (>10 ml)[2,3]. The
identification of two out of three parameters allows to
give the diagnosis of PCOS.* Correspondence: rosalbinoisabella@gmail.com
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distribution, and reproduction in any mediumSince 1980, it is known that PCOS is associated with
insulin resistance (IR). The recognition of this associ-
ation has prompted extensive investigation on the rela-
tionship between insulin and gonadal function [4].
Insulin acts synergistically with luteinizing hormone
(LH) to enhance the androgen production of theca cells
[5]. Furthermore, it is able to reduce circulating levels of
sex hormone binding globulin (SHBG), leading to
increased levels of free testosterone [6]. It has become
clear that this syndrome has major metabolic as well as
reproductive morbidities. Although the consensus meet-
ing has decided to exclude IR from the diagnostic cri-
teria, IR affects 50-80% of the patients with PCOS
regardless BMI[7]. Accordingly, this association has led
to the treatment of PCOS women with insulin sensitiz-
ing agents such as troglitazone [8], inositol [9,10], met-
formin [11] for restoring spontaneous ovulation.
In particular, several lines of evidence suggest that a
deficiency of inositol, which is a second messenger ofCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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[12]. Inositol is a polyalcohol classified as insulin
sensitizer and existing as nine stereoisomers, two of
which are currently used in PCOS treatment: myo-
inositol (MI) and D-chiro-inositol (DCI) [9,13]. Both
stereoisomers show an insulin-like action in vivo exert-
ing the function of insulin mediators as inositolphospho-
glycans (IPGs) [14]. Indeed, MI is the most abundant
form of inositol in humans while DCI is synthetized by
an insulin-dependent epimerase that converts MI to
DCI. Interestingly, every organ has a specific MI/DCI
ratio likely linked to its specific needs (i.e. specific bio-
logical processes controlled be each inositol). Indeed, be-
side the common features, both inositols have specific
action. DCI is able to induce glycogen synthesis; in par-
ticular, high DCI levels were identified only in glycogen
storage tissues[14]. On the other hand, MI plays a cru-
cial role at ovarian level. Recently, Chiu et al. have
reported that high concentrations of MI positively cor-
relate with high quality and mature oocytes and a recent
review clearly summarized the important role of MI in
human reproduction [15][16]. Furthermore, MI supple-
mentation during IVF protocols has been shown to im-
prove oocyte quality and reduce the number of IU of
FSH necessary for ovarian stimulation [17,18].
Oocyte quality is the main factor influencing the
chance of a pregnancy; indeed, poor oocyte quality is a
cause of infertility as well as an important obstacle for a
successful in vitro fertilization (IVF).
Additional data have also shown that DCI supplemen-
tation at the dose of 1,2 g/die has no influence on ovar-
ian response to exogenous FSH [19]. The aim of the
present study was to better investigate whether DCI has
a role at ovarian level.
Materials and methods
Patients
A total of 54 women, aged <40 years and diagnosed with
PCOS according to Rotterdam criteria, were enrolled in
this study. All the subjects were selected among patients
undergoing ICSI procedure that was suggested after
evaluation of two different sperm samples of the male
partner. ICSI patients were selected in order to minimize
differences between semen samples. Patients with insulin
resistance and/or hyperglycaemia were excluded from
the study. In particular, insulin resistance was assessed
by calculating the HOMA index, the cut-off defining in-
sulin resistance was 3.2. Concomitantly hyperglycaemia
was defied as glucose level > than 140 mg/dl after 2h
OGTT Patients were randomly divided into 5 groups
(n = 10-12): a placebo group, and 4 groups (A-D) that
received 300-600-1200-2400 mg of DCI (Interquim, s.a.,
Barcelona, Spain) daily respectively. All treatments were
carried out for 8 weeks before follicle stimulatinghormone (rFSH) administration. The randomization
procedure was performed using a computer-based pro-
gram. The Institutional Ethical Committee approved the
protocol, and all patients gave a written informed con-
sent before entering the study.
Controlled ovarian hyperstimulation
All patients underwent pituitary desensitization by sub-
cutaneous (s.c.) administration of the gonadotropin re-
leasing hormone (GnRH) agonist (Decapeptyl; Ipsen,
Paris, France) from midluteal phase until the day of
intramuscular (i.m.) administration of 10,000 IU of
human chorionic gonadotropin (hCG). Then, controlled
ovarian hyperstimulation was performed in all patients
by the administration of recombinant FSH (Gonal-F;
Merck-Serono, Geneva, Switzerland). Starting dose was
150 IU per day. Patients were monitored by measuring
the plasma concentration of 17β-Estradiol 2 (17β-E2)
and the size of follicles on day 5 of the stimulation. The
dosage of gonadotropin was adjusted according to the
individual response. The 10,000 IU hCG was injected i.
m. in all patients when serum 17β-E2 exceeded 200 pg
per follicle and at least three follicles with a minimum
diameter of 18 mm were found. Cycles were cancelled if
E2 levels were >4,000 pg/mL, due to increased risk of
ovarian hyperstimulation syndrome (OHSS).
ICSI procedure
According to Italian IVF law, a maximum of three
oocytes per patient were injected, while spare mature
oocytes were cryopreserved according to protocols
described in previous studies [20]. Oocyte and sperm
preparation for conventional ICSI procedure have been
thoroughly described elsewhere [21]. Concerning ICSI,
cumulus and corona radiata cells were immediately
removed after retrieval by a short exposure to HEPES-
buffered medium (Quinn’s Advantage Hepes Medium;
Sage IVF, Trumbull, CT, USA) containing 20 IU/mL
hyaluronidase (Sage IVF) and by gentle aspiration in and
out of a Pasteur pipette following by mechanical clean-
ing from the remaining surrounding cumulus cells by as-
piration using a denuding pipette (Denuding Flexi-Pet;
Cook, Brisbane, Australia) with a 170–130 mm diameter.
The denuded oocytes were then assessed for their mei-
otic maturation status. In preparation for ICSI, oocytes
with an extruded first polar body presumably at the
metaphase II stage (MII) were selected (in a maximum
of three) for the fresh cycle and spare MII oocytes were
cryopreserved, if required [22].
Luteal phase
Intramuscular administration of 50 mg daily progester-
one in-oil was started on the day of ovum pick-up, and
the treatment was performed daily until either a serum
Table 1 Baseline characteristics of patients
PLACEBO A (DCI 300mg) B (DCI 600mg) C (DCI 1200mg) D (DCI 2400mg) p
No. of patients 11 10 11 10 12 NS
Age (years) 36.9 ± 1.5 36.8 ± 1.6 36.9 ± 1.52 36.7 ± 1.57 37.0 ± 1.25 NS
BMI (kg/m2) 24.4 ± 2.8 25.2 ± 3.5 24.7 ± 3.5 25.1 ± 3.1 25.6 ± 2.9 NS
Duration of infertility (months) 48.2 ± 9.4 49.4 ± 7.6 50.0 ± 7.2 49.9 ± 6.1 48.9 ± 8.8 NS
Data are expressed as mean ± SD.
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beat was sonographically confirmed.
Statistical analysis
Baseline characteristics and ovum pick-up outcomes
were analyzed using One-way ANOVAs. The source of
the detected significances was determined by Bonferroni
post hoc test. P values less than 0.05 were considered
statistically significant.
Results
Patients matching the inclusion criteria were rando-
mized into five groups by a computer program. One-way
ANOVA revealed no significant differences between
groups in mean age, Body Mass Index at baseline
(Table 1). Total r-FSH units and number of days of
stimulation differed between the groups. In particular,
compared to the placebo group, the FSH IU adminis-
tered were increased significantly in the two groups that
received the higher doses of DCI (Table 2). Estradiol
levels at hCG administration were significantly different
only in the group D (women treated with 1.2g of DCI
Table 2). The total number of oocytes retrieved were
similar between the groups, while the number of imma-
ture oocytes (Figure 1, P < 0.003) and number of MII
oocytes (Figure 2, P = 0.0013) significantly differed. In-
deed, the number of immature oocytes was significantly
increased in the three groups that received the higher
doses of DCI (P < 0.04). Concurrently, the number of
MII oocytes was significantly lower in the D group com-
pared to placebo group (P < 0.001). Noteworthy, the
number of grade I embryos was significantly reduced by
DCI supplementation (P = 0.004). Embryo quality wasTable 2 Clinical Data
PLACEBO A (DCI
No. Oocytes retrieved 8.99 ± 2.52 9.20 ± 2
Total rFSH (IU) 2239.7 ± 181.55 2379.1 ±
17β-E2 levels (pg/ml)on hGC administration 1429.69 ± 1118.43 1443.43
Stimulation (days) 11.4 ± 1.2 12.1 ± 0
No. Of cycles cancelled 1 1
Data are expressed as mean ± SD.
17β-E2 levels decreases in D group.
*, P < 0.05 vs placebo. Stimulation days increase in B,C,D group (300, 600, 1200 mg
*, P < 0.05 vs placebo, **, P < 0.01 vs placebo.significantly reduced in women treated with 600, 1200
and 2400 mg of DCI (Figure 3).
Discussion
In the present study we were able to show that DCI nega-
tively affects oocyte quality. Indeed, increasing DCI dosage
progressively worsens oocyte quality and ovarian response
in non-obese and non insulin resistant PCOS women. Lit-
erature data clearly show that the two inositol stereoi-
somers have different physiological roles: while DCI is
crucial for glycogen synthesis, MI increases glucose cellular
uptake [12]. Interestingly, each tissue has its own MI/DCI
ratio and the relative amount of each inositol in a certain
tissue reflects inositol(s) specific functions. Indeed, high
DCI levels (always lower than MI) are present only in
glycogen storage tissues (fat, liver and muscle), while very
low levels of DCI are characteristic of tissues that have high
glucose utilization, likely because they need to “have a high
energy status” (brain and heart) [14]. Recently a new manu-
script pointed out that one of the causes of poor oocyte
quality in PCOS women might be the reduced energy me-
tabolism [23]. Indeed, literature data have shown that in
PCOS women, genes involved in the glucose uptake path-
way are downregulated at ovarian level [24]. These data are
indeed in line with the findings of Carlomagno et al., that
in a comparative study (MI vs. DCI) highlighted that only
MI has an action at ovarian level; since MI is responsible of
glucose cell uptake, likely it improves ovary energy status
and therefore, it is able to improve oocyte quality [19,23].
In vivo, DCI is synthetized by an epimerase that converts
MI into DCI and, depending on the specific needs of the
two different molecules, each tissue has a typical conversion
rate. In particular, it has been shown that the ratio of these300 mg) B (DCI 600mg) C (DCI 1200mg) D (DCI 2400mg)
.46 9.13 ± 2.99 7.83 ± 2.78 7.23 ± 2.77
353.80 2305.9 ± 150.19 2368.5 ± 235.77* 2983.0 ± 219.80**
± 1087.43 1350.06 ± 513.04 1530.85 ± 433.17 1490.24 ± 253.21 *




























Figure 1 Effects of DCI (300, 600, 2400 mg) on number of
immature oocytes. Data are expressed as mean± SD. Number of
immature oocytes increases after DCI administration. *, P <0.05 vs.


























Figure 3 Effects of DCI (300, 600, 2400 mg) on number of
embryo grade I. Data are expressed as mean± SD. Number of
embryo grade I decreases after DCI administration. **, P <0.01 vs.
placebo, ***, P <0.001 vs. placebo (n = 10-11 per group).
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in subjects with type 2 diabetes, the DCI/MI ratio is
reduced and less DCI is synthetized, due to a reduction in
the epimerase activity [25,26]. Unlike other tissues such as
muscle and liver, ovary never become insulin resistant
[27,28]. Therefore, it can be speculated that PCOS patients
with hyperinsulinemia probably present an enhanced MI to
DCI epimerization rate in the ovary that would result in an
increased DCI/MI ratio (i.e., overproduction of DCI), and
in a MI deficiency. This MI depletion could eventually be
responsible for the poor oocyte quality observed in these
patients [29]. In addition, the positive effects of MI supple-
mentation [17-19,30] might be explained by the fact that re-
storing MI levels will improve ovarian response to FSH;
furthermore, since MI is responsible for glucose cell intake,
energy status will be restored as well. Nestler et al. in 1999
showed for the first time that administration of DCI (1.2 g/






















Figure 2 Effects of DCI (300, 600, 2400 mg) on number of MII
oocytes. Data are expressed as mean± SD. Number of MII occytes
decreases after DCI administration. **P <0.01 vs.placebo, ***, P
<0.001 vs.placebo (n = 10-11 per group).4 weeks of treatment, although no data on menstrual regu-
larity were reported[9]. However, in a second study con-
ducted by the same authors, DCI dosage was doubled
(2400 mg/die) and authors were not able to confirm their
pervious findings.[31] Our results seems to be in line with
the DCI paradox hypothesis [29]. Indeed, increasing DCI
dosage progressively negatively influences oocyte and
embryo quality. Similar results have been obtained by treat-
ing PCOS woman scheduled for IVF with metformin, 500
mg three times per day[32]. Metformin decreased the num-
ber of dominant follicles, retrieved oocytes, and MII
oocytes, despite increased IU of gonadotropin were admi-
nistered. Baillargoen et al. showed that metformin increased
the insulin-stimulated release of DCI-phosphoglycans;
therefore, we could hypothesize that metformin promotes
glycogen synthesis and further reduces ovary energy status
through DCI phosphoglycans [33]. Based on this evidence,
we can speculate on the reason why Nesteler had opposite
results in the two trials. In the first study, DCI supplemen-
tation restored ovulation probably due to a peripheral ac-
tion of DCI, allowing to restore epimerase physiological
rating into the ovary. In the second trial, the lack of positive
effects after 2400mg DCI supplementation was probably
due to an overload of DCI (pre-existent high levels of DCI
in the ovary and supplementation). In conclusion, we have
shown that DCI supplementation reduces oocyte quality;
therefore the administration of DCI cannot be considered
as an appropriate approach to improve IVF outcomes in
PCOS patients.
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